Soooo… What Is Zurzuvae?
By Dr. Savannah Patel MD | Reproductive Psychiatry
Zurzuvae (zuranolone) is a medication specifically approved to treat postpartum depression in adults. It is also notable because it is taken for just 14 days, rather than being started as a medication you automatically stay on for months or years.
That makes it very different from the antidepressants most people are familiar with.
Before we get into how it works, it helps to talk about postpartum depression itself.
First: Postpartum Depression Is More Than the “Baby Blues”
Feeling emotional, tearful, overwhelmed, or irritable in the first several days after delivery is incredibly common. The “baby blues” usually come on shortly after birth and tend to improve within about two weeks.
Postpartum depression is different.
It can look like persistent sadness, anxiety, irritability, hopelessness, guilt, feeling disconnected from your baby, losing interest in things you normally enjoy, or simply feeling like you are not yourself.
For some women, the most prominent symptom is not sadness at all. It might be intense anxiety, panic, intrusive thoughts, insomnia even when the baby is sleeping, or a constant sense of dread.
And postpartum depression does not always begin after delivery. Many depressive episodes actually begin during pregnancy and continue into the postpartum period. That timing matters, because the postpartum period involves one of the most dramatic hormonal shifts the body ever experiences.
So, Back to Zurzuvae…
It was approved by the FDA in 2023 as the first oral medication specifically approved for postpartum depression. You take it once a day in the evening, with a fat-containing meal, for 14 days. The usual recommended dose is 50 mg daily. That 14-day treatment course is one of the things that makes it so interesting.
Traditional antidepressants such as SSRIs can be very effective for postpartum depression, but they usually take several weeks to begin working and are often continued for months after someone improves. Zurzuvae works through a different system in the brain and seems to act much faster.
How Does It Work?
Nerd time…this is where the neuroscience gets really interesting.
During pregnancy, levels of the hormone progesterone rise dramatically. Progesterone is converted into a naturally occurring neurosteroid called allopregnanolone. Allopregnanolone interacts with GABA-A receptors in the brain. GABA is essentially one of the brain’s major calming systems. It helps regulate stress, anxiety, sleep, and emotional stability. After delivery, progesterone and allopregnanolone levels fall very rapidly.
Most women adapt to that hormonal shift without developing depression. But researchers believe that in some women, the brain may have difficulty adapting to this abrupt change in neurosteroid signaling.
Zuranolone is a synthetic neuroactive steroid that acts as a positive allosteric modulator of GABA-A receptors. In plain English, the zuranolone flattens the slope of the hormonal rollercoaster.
That is one reason zuranolone is fundamentally different from an SSRI.
SSRIs primarily target serotonin signaling. Zuranolone is targeting a pathway that may be particularly relevant to the biology of the postpartum period itself.
How Quickly Does It Work?
This is the part that makes me excited.
In one major randomized clinical trial of women with postpartum depression, improvement was seen as early as day 3. By day 15, women taking zuranolone had a significantly greater reduction in depression scores than women taking placebo, and the difference was still present at day 45—about a month after the medication had been stopped.
In that trial, 72% of women taking zuranolone met criteria for treatment response at day 15 compared with 48% taking placebo, and 45% reached remission compared with 23% in the placebo group.
However, that unfortunately doesn’t mean everyone responds, and it doesn’t mean everyone stays well indefinitely after one course. BUT having a treatment that can potentially improve symptoms within days rather than weeks is a meaningful development in perinatal psychiatry.
Does Zurzuvae Replace SSRIs?
No… and I think this is an important point.
SSRIs remain very effective treatments for postpartum depression and have decades of clinical experience behind them. They may still be the right first choice for many women, particularly if someone has responded well to an SSRI in the past or has depression or anxiety that predates pregnancy. The Zurzuvae just gives us another option.
It may be particularly appealing when symptoms are more severe, when we would like improvement more quickly, or when someone is interested in a time-limited treatment rather than immediately committing to a long-term daily antidepressant.
It can also be used alongside an existing antidepressant in certain circumstances. Sometimes a psychiatrist may recommend both: a faster-acting treatment like zuranolone to help someone improve quickly while a longer-term treatment plan is being put into place.
The important thing is that postpartum depression treatment is not one-size-fits-all.
What Does the New ACOG Guidance Say?
ACOG recently updated its clinical guidance specifically addressing zuranolone and brexanolone for postpartum depression.
Brexanolone is another neuroactive steroid treatment for postpartum depression, but it is given as a prolonged IV infusion. Zuranolone is the oral version of this newer treatment approach, which makes it far more practical for many patients.
The updated guidance focuses on the use of these medications when depression begins in the third trimester or within four weeks postpartum.
At the same time, ACOG continues to emphasize individualized decision-making, because we still have unanswered questions about exactly who benefits most, how long the effect lasts for every patient, and whether or when retreatment might be needed.
What Are the Side Effects?
The most common side effects include:
sleepiness
dizziness
fatigue
diarrhea
cold-like symptoms
urinary tract infections
Sedation is the side effect I talk about most with patients. In one of the FDA trials, somnolence occurred in 36% of women receiving the 50 mg dose compared with 6% receiving placebo.
Because of that, Zurzuvae carries an important warning about driving. You should not drive or operate heavy machinery for at least 12 hours after each dose, and importantly, people may not always be able to accurately judge how impaired they are.
That practical piece matters a lot in postpartum life, especially when someone is caring for a newborn overnight. I always recommend that a mom has additional support in newborn caregiving during the 14-day regimen.
Alcohol and other medications that cause sedation can also increase those effects, so your prescriber needs to review everything else you are taking.
Can You Breastfeed While Taking It?
This is one of the first questions many mothers understandably ask.
Zuranolone does pass into breast milk. At this point, we don’t have much information about what that exposure means for a breastfed infant, and we do not yet have extensive long-term breastfeeding data.
ACOG currently recommends an individualized discussion. Some women may continue breastfeeding during the 14-day course, while others may choose to temporarily pause breastfeeding and resume one week after the last dose. This is a good example of why reproductive psychiatry is rarely about saying a medication is simply “safe” or “unsafe.”
The decision depends on the severity of the mother’s illness, the benefits of treatment, the importance of breastfeeding to that individual patient, the available data, and the alternatives.
Is Zurzuvae a Cure for Postpartum Depression?
That would be irresponsible to claim. Zurzuvae is a powerful new treatment option, but our long-term data are still developing.
The strongest evidence we have right now shows meaningful improvement during treatment and through approximately 45 days of follow-up. We have much less information about what happens six months or a year later, which patients may relapse, and whether some women will benefit from repeat treatment.
It also does not replace the other parts of postpartum mental health care. Sleep, social support, psychotherapy, treatment of anxiety, support from a partner or family, and sometimes longer-term medication remain incredibly important.
Who Might Be a Good Candidate?
That decision is individualized, but I especially consider the conversation when someone has: significant postpartum depressive symptoms, needs symptom relief more quickly, has not responded adequately to another treatment, or has a clinical picture that suggests a neurosteroid treatment may be particularly useful.
It is also worth considering a patient’s history.
Someone with recurrent major depression may still benefit from a traditional antidepressant because we are not only treating the current episode—we are also thinking about relapse prevention.
On the other hand, someone whose depression appears tightly connected to pregnancy and the postpartum hormonal transition may have a very different treatment discussion.
This is where reproductive psychiatry becomes especially helpful: the goal is not simply to choose a medication. It is to understand why the episode happened, what the patient’s psychiatric history looks like, what her reproductive stage is, and what the safest and most effective longer-term plan looks like.
The Bottom Line
Zurzuvae is one of the most exciting developments we have had in perinatal psychiatry in years.
It is the first oral medication specifically approved for postpartum depression, it is taken for only 14 days, and it works through a neurosteroid pathway that is closely tied to the enormous hormonal transition that occurs after pregnancy.
Even more importantly, it represents a shift in how we think about postpartum depression. Postpartum depression is not simply “regular depression that happens after having a baby.” For many moms, reproductive hormones and the brain’s response to rapid hormonal change appear to be an important part of the story. Having treatments that specifically target those biological pathways gives us another tool—and another reason to take postpartum mental health seriously.
At Patel Mind and Body, reproductive psychiatry care includes evaluation and treatment of depression and anxiety during pregnancy and postpartum, medication risk-benefit consultations, and individualized treatment planning based on each woman’s psychiatric history, symptoms, reproductive goals, and preferences.
If you are struggling after having a baby, you do not need to wait until symptoms become severe before asking for help. There are more treatment options available now than ever before.
This article is for educational purposes and does not replace individualized medical advice. If you are having thoughts of harming yourself or your baby, experiencing severe confusion, paranoia, hallucinations, or feeling disconnected from reality, seek urgent medical attention.
References: American College of Obstetricians and Gynecologists. Zuranolone and Brexanolone for the Treatment of Postpartum Depression. Obstetrics & Gynecology. 2026;147(1):e24-e28. PubMed FDA. FDA Approves First Oral Treatment for Postpartum Depression. U.S. Food and Drug Administration Deligiannidis KM, et al. Zuranolone for the Treatment of Postpartum Depression. American Journal of Psychiatry.
